American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Mozaffarian, 2016, Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association, Circulation., 133, e38
Nicholls, 2004, The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol, Semin Vasc Med., 4, 187, 10.1055/s-2004-835377
Wild, 2009, Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study, Atherosclerosis., 203, 604, 10.1016/j.atherosclerosis.2008.07.028
Rodriguez-Colon, 2009, Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study, Stroke., 40, 200, 10.1161/STROKEAHA.108.523035
Cohen, 2010, 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. (Erratum in: Am J Cardiol. 2010;106:1826), Am J Cardiol., 106, 969, 10.1016/j.amjcard.2010.05.030
Jellinger, 2012, American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis, Endocr Pract., 18, 1, 10.4158/EP.18.S1.1
Handelsman, 2011, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan, Endocr Pract., 17, 1, 10.4158/EP.17.S2.1
Mechanick, 2014, American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists - 2014 Update and the AACe G4G Program, Endocr Pract., 20, 692, 10.4158/EP14166.PS
Brunzell, 2002, National Institutes of Health; National Heart Lung, and Blood Institute; 2002 National Cholesterol Education Program, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final Report
Brunzell, 2008, Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Diabetes Care., 31, 811, 10.2337/dc08-9018
Stamler, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA., 256, 2823, 10.1001/jama.1986.03380200061022
Neaton, 1992, Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group, Arch Intern Med., 152, 1490, 10.1001/archinte.1992.00400190110021
Grundy, 1998, Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction, American Heart Association. Circulation., 97, 1876
Einhorn, 2003, American College of Endocrinology position statement on the insulin resistance syndrome, Endocr Pract., 9, 237, 10.4158/EP.9.S2.5
2004, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Weiner, 2004, Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies, J Am Soc Nephrol., 15, 1307, 10.1097/01.ASN.0000123691.46138.E2
Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet., 364, 937, 10.1016/S0140-6736(04)17018-9
2005, American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome, Endocr Pract., 11, 126
Cromwell, 2007, LDL Particle number and risk of future cardiovascular disease in the Framingham offspring study implications for LDL management, J Clin Lipidol., 1, 583, 10.1016/j.jacl.2007.10.001
Kastelein, 2008, Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment, Circulation., 117, 3002, 10.1161/CIRCULATIONAHA.107.713438
2017, Diabetes Care, 40, S1
Stone, 1996, Lipid management: current diet and drug treatment options, Am J Med, 101, 4A40S, 10.1016/S0002-9343(96)00319-1
Stevens, 2001, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56), Clin Sci, 101, 671, 10.1042/cs1010671
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet., 360, 7, 10.1016/S0140-6736(02)09327-3
Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet., 360, 1623, 10.1016/S0140-6736(02)11600-X
Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation., 110, 227, 10.1161/01.CIR.0000133317.49796.0E
Lloyd-Jones, 2004, Framingham and risk score prediction of lifetime risk for coronary heart disease, Am J Cardiol., 94, 20, 10.1016/j.amjcard.2004.03.023
Ridker, 2005, Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial, J Am Coll Cardiol., 45, 1644, 10.1016/j.jacc.2005.02.080
Barter, 2006, Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel, J Intern Med., 259, 247, 10.1111/j.1365-2796.2006.01616.x
Smith, 2006, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. (Erratum in: Circulation. 2006;113:e847.), Circulation, 113, 2363, 10.1161/CIRCULATIONAHA.106.174516
Ridker, 2007, Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score, JAMA., 297, 611, 10.1001/jama.297.6.611
Boekholdt, 2014, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, J Am Coll Cardiol., 64, 485, 10.1016/j.jacc.2014.02.615
Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med., 372, 2387, 10.1056/NEJMoa1410489
Mosca, 2004, Evidence-based guidelines for cardiovascular disease prevention in women, Circulation., 109, 672, 10.1161/01.CIR.0000114834.85476.81
2016, Hard Coronary Heart Disease (10 Year Risk)
2016, MESA 10-Year CHD Risk with Coronary Artery Calcification
2016, Reynolds Risk Score: Calculating Heart and Stroke Risk for Women and Men
2016, UKPDS Risk Engine University of Oxford Diabetes Trial Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism
Smith, 2007, Multiple risk factors for cardiovascular disease and diabetes mellitus, Am J Med., 120, S3, 10.1016/j.amjmed.2007.01.002
Qureshi, 2004, The relative impact of inadequate primary and secondary prevention on cardiovascular mortality in the United States, Stroke., 35, 2346, 10.1161/01.STR.0000141417.66620.09
Betteridge, 1996, Lipid management: past, present, and future, Br J Clin Pract Suppl., 77A, 1
Assmann, 1997, New and classical risk factors--the Münster heart study (PROCAM), Eur J Med Res., 2, 237
Van Horn, 1997, Diet and cardiovascular disease prevention: what works?, Ann Behav Med., 19, 197, 10.1007/BF02892285
Assmann, 1998, The Münster Heart Study (PROCAM). Results of follow-up at 8 years, Eur Heart J, 19, A2
Pfeffer, 1999, Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events, J Am Coll Cardiol., 33, 125, 10.1016/S0735-1097(98)00522-1
1994, Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet., 344, 1383
Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet., 364, 685, 10.1016/S0140-6736(04)16895-5
Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. (Erratum in: JAMA. 2005;28:3092), JAMA, 294, 2437, 10.1001/jama.294.19.2437
Ray, 2005, Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial, J Am Coll Cardiol., 46, 1405, 10.1016/j.jacc.2005.03.077
Waters, 2006, Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study, J Am Coll Cardiol., 48, 1793, 10.1016/j.jacc.2006.07.041
Ford, 2016, Long- Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study, Circulation., 133, 1073, 10.1161/CIRCULATIONAHA.115.019014
Zimmerman, 2015, How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control?, Am Health Drug Benefits., 8, 436
Barrett-Connor, 1984, Family history of heart attack as an independent predictor of death due to cardiovascular disease, Circulation., 69, 1065, 10.1161/01.CIR.69.6.1065
Shea, 1984, Family history as an independent risk factor for coronary artery disease, J Am Coll Cardiol., 4, 793, 10.1016/S0735-1097(84)80408-8
Sesso, 2001, Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women, Circulation., 104, 393, 10.1161/hc2901.093115
Superko, 1998, Did grandma give you heart disease? The new battle against coronary artery disease, Am J Cardiol., 82, 34Q, 10.1016/S0002-9149(98)00771-1
Fornage, 2004, Parental history of stroke and myocardial infarction predicts coronary artery calcification: The Coronary Artery Risk Development in Young Adults (CARDIA) study, Eur J Cardiovasc Prev Rehabil., 11, 421, 10.1097/00149831-200410000-00011
Nasir, 2004, Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history, Circulation., 110, 2150, 10.1161/01.CIR.0000144464.11080.14
Juonala, 2006, Young adults with family history of coronary heart disease have increased arterial vulnerability to metabolic risk factors: the Cardiovascular Risk in Young Finns Study, Arterioscler Thromb Vasc Biol., 26, 1376, 10.1161/01.ATV.0000222012.56447.00
Goldstein, 1995, Familial hypercholesterolemia, 1981
Haralambos, 2016, Diagnostic scoring for familial hypercholesterolaemia in practice, Curr Opin Lipidol., 27, 367, 10.1097/MOL.0000000000000325
Turgeon, 2016, Familial hypercholesterolemia: Review of diagnosis, screening, and treatment, Can Fam Physician., 62, 32
Shantha, 2016, Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids, Clin Pharmacol Ther., 99, 59, 10.1002/cpt.281
Raal, 2015, PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, Lancet., 385, 331, 10.1016/S0140-6736(14)61399-4
Farnier, 2016, Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial, Atherosclerosis., 244, 138, 10.1016/j.atherosclerosis.2015.11.010
Garber, 2016, Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary, Endocr Pract., 22, 84, 10.4158/EP151126.CS
Castelli, 1992, Lipids and risk of coronary heart disease, The Framingham Study. Ann Epidemiol., 2, 23, 10.1016/1047-2797(92)90033-M
Kinosian, 1994, Cholesterol and coronary heart disease: predicting risks by levels and ratios, Ann Intern Med., 121, 641, 10.7326/0003-4819-121-9-199411010-00002
Natarajan, 2003, Cholesterol measures to identify and treat individuals at risk for coronary heart disease, Am J Prev Med., 25, 50, 10.1016/S0749-3797(03)00092-8
Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med., 357, 1301, 10.1056/NEJMoa064278
McLaughlin, 2003, Use of metabolic markers to identify overweight individuals who are insulin resistant, Ann Intern Med., 139, 802, 10.7326/0003-4819-139-10-200311180-00007
Gualandri, 1985, AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission, Am J Hum Genet., 37, 1083
Sirtori, 2001, Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study, Circulation., 103, 1949, 10.1161/01.CIR.103.15.1949
Rubenfire, 1998, Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors, Prog Cardiovasc Dis., 41, 95, 10.1016/S0033-0620(98)80007-8
Wilson, 1988, High density lipoprotein cholesterol and mortality, The Framingham Heart Study. Arteriosclerosis., 8, 737
Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation., 79, 8, 10.1161/01.CIR.79.1.8
Wilson, 1998, Prediction of coronary heart disease using risk factor categories, Circulation., 97, 1837, 10.1161/01.CIR.97.18.1837
Mackness, 1993, Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase, Atherosclerosis., 104, 129, 10.1016/0021-9150(93)90183-U
Harper, 1999, New perspectives on the management of low levels of high-density lipoprotein cholesterol, Arch Intern Med., 159, 1049, 10.1001/archinte.159.10.1049
Schaefer, 1989, Plasma lipoproteins in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: results from the Framingham Heart Study, Metabolism., 38, 293, 10.1016/0026-0495(89)90113-3
Nikkilä, 1990, High-density lipoprotein cholesterol and longevity, Age Ageing., 19, 119, 10.1093/ageing/19.2.119
Nikkilä, 1991, Elevated high-density-lipoprotein cholesterol and normal triglycerides as markers of longevity, Klin Wochenschr., 69, 780, 10.1007/BF01744268
Barter, 2004, HDL: a recipe for longevity, Atheroscler Suppl., 5, 25, 10.1016/j.atherosclerosissup.2004.03.003
Gotto, 1999, Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives, Arch Intern Med., 159, 1038, 10.1001/archinte.159.10.1038
1995, National Diabetes Data Group. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America, 2nd Edition
Haffner, 1998, Management of dyslipidemia in adults with diabetes, Diabetes Care., 21, 160, 10.2337/diacare.21.1.160
Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med., 339, 229, 10.1056/NEJM199807233390404
Di Angelantonio, 2015, Association of cardiometabolic multimorbidity with mortality, JAMA., 314, 52, 10.1001/jama.2015.7008
Frohlich, 2000, Dyslipidaemia and coagulation defects of insulin resistance, Int J Clin Pract Suppl., 14
Sowers, 2001, Diabetes, hypertension, and cardiovascular disease: an update. (Erratum in: Hypertension. 2001;37:1350), Hypertension, 37, 1053, 10.1161/01.HYP.37.4.1053
Stehouwer, 2002, Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death, Diabetes., 51, 1157, 10.2337/diabetes.51.4.1157
Targher, 2005, Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy, Diabet Med., 22, 999, 10.1111/j.1464-5491.2005.01562.x
Boden, 2007, Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation, Curr Diab Rep., 7, 223, 10.1007/s11892-007-0035-1
Garber, 2008, Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists, Endocr Pract., 14, 933, 10.4158/EP.14.7.933
Lehto, 1999, Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy, Arterioscler Thromb Vasc Biol., 19, 1014, 10.1161/01.ATV.19.4.1014
Nathan, 2005, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med., 353, 2643, 10.1056/NEJMoa052187
Pambianco, 2006, The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience, Diabetes., 55, 1463, 10.2337/db05-1423
Secrest, 2010, Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes, Diabetes., 59, 3216, 10.2337/db10-0862
de Ferranti, 2014, Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association, Diabetes Care., 37, 2843, 10.2337/dc14-1720
Nikkilä, 1978, Serum lipids and lipoproteins in insulin-treated diabetes. Demonstration of increased high density lipoprotein concentrations, Diabetes., 27, 1078, 10.2337/diab.27.11.1078
Taskinen, 1992, Quantitative and qualitative abnormalities in diabetes mellitus, Diabetes., 41, 12, 10.2337/diab.41.2.S12
Valsania, 1991, Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus, Am Heart J., 122, 695, 10.1016/0002-8703(91)90513-H
Chun, 1997, The impact of diabetes on survival among patients with first myocardial infarction, Diabetes Care., 20, 704, 10.2337/diacare.20.5.704
Rozenman, 1997, Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation, J Am Coll Cardiol., 30, 1420, 10.1016/S0735-1097(97)00342-2
Miettinen, 1998, Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group, Diabetes Care., 21, 69, 10.2337/diacare.21.1.69
Savage, 1988, Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor, Am J Cardiol., 62, 665, 10.1016/0002-9149(88)91199-X
Dabelea, 2003, Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. (Erratum in: Diabetes. 2004;53:2177), Diabetes, 52, 2833, 10.2337/diabetes.52.11.2833
Libby, 2005, Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus, Circulation., 111, 3489, 10.1161/CIRCULATIONAHA.104.529651
Orchard, 1998, Cardiovascular disease in insulin dependent diabetes mellitus: similar rates but different risk factors in the US compared with Europe, Int J Epidemiol., 27, 976, 10.1093/ije/27.6.976
Borch-Johnsen, 1987, Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus, Br Med J (Clin Res Ed), 294, 1651, 10.1136/bmj.294.6588.1651
Alexander, 2003, Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210
Mackness, 2006, High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease, Atherosclerosis., 186, 396, 10.1016/j.atherosclerosis.2005.07.028
Baigent, 2010, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5
Handelsman, 2015, American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015, Endocr Pract., 21, 1, 10.4158/EP15672.GLSUPPL
Program, 1994, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), Circulation., 89, 1333, 10.1161/01.CIR.89.3.1333
Andersson, 1998, Survival in treated hypertension: follow up study after two decades, BMJ., 317, 167, 10.1136/bmj.317.7152.167
Nanchahal, 2000, Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women, J Hypertens., 18, 833, 10.1097/00004872-200018070-00003
Almgren, 2005, Stroke and coronary heart disease in treated hypertension - a prospective cohort study over three decades, J Intern Med., 257, 496, 10.1111/j.1365-2796.2005.01497.x
Boggia, 2007, Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study, Lancet., 370, 1219, 10.1016/S0140-6736(07)61538-4
1996, 1
Freeman, 1993, Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution, Eur J Clin Invest., 23, 630, 10.1111/j.1365-2362.1993.tb00724.x
Axelsen, 1995, Lipid intolerance in smokers, J Intern Med., 237, 449, 10.1111/j.1365-2796.1995.tb00869.x
Razay, 1995, Smoking habits and lipoproteins in British women, QJM., 88, 503
Cullen, 1998, Smoking, lipoproteins and coronary heart disease risk. Data from the Münster Heart Study (PROCAM), Eur Heart J., 19, 1632, 10.1053/euhj.1998.1086
Mero, 1998, Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities, J Lipid Res., 39, 1493, 10.1016/S0022-2275(20)32531-1
Schuitemaker, 2002, Relationship between smoking habits and low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, and triglycerides in a hypercholesterolemic adult cohort, in relation to gender and age, Clin Exp Med., 2, 83, 10.1007/s102380200011
Maeda, 2003, The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis, Prev Med., 37, 283, 10.1016/S0091-7435(03)00110-5
NHLBI, 1998
Ogden, 2006, Prevalence of overweight and obesity in the United States, 1999-2004, JAMA., 295, 1549, 10.1001/jama.295.13.1549
Lamon-Fava, 1996, Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study, Arterioscler Thromb Vasc Biol., 16, 1509, 10.1161/01.ATV.16.12.1509
Thomas, 2005, Cardiovascular mortality in overweight subjects: the key role of associated risk factors, Hypertension., 46, 654, 10.1161/01.HYP.0000184282.51550.00
Onat, 2007, Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study, Metabolism., 56, 348, 10.1016/j.metabol.2006.10.016
Onat, 2007, Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study, Atherosclerosis., 191, 182, 10.1016/j.atherosclerosis.2006.03.012
Nieves, 2003, The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat, Diabetes., 52, 172, 10.2337/diabetes.52.1.172
Carr, 2004, Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome, Diabetes., 53, 2087, 10.2337/diabetes.53.8.2087
de Graaf, 1991, Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects, Arterioscler Thromb., 11, 298, 10.1161/01.ATV.11.2.298
Tribble, 1992, Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size, Atherosclerosis., 93, 189, 10.1016/0021-9150(92)90255-F
Chait, 1993, Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B, Am J Med., 94, 350, 10.1016/0002-9343(93)90144-E
Ballantyne, 1998, Low-density lipoproteins and risk for coronary artery disease, Am J Cardiol., 82, 3Q, 10.1016/S0002-9149(98)00769-3
Krauss, 1998, Triglycerides and atherogenic lipoproteins: rationale for lipid management, Am J Med., 105, 58S, 10.1016/S0002-9343(98)00213-7
Krauss, 2004, Lipids and lipoproteins in patients with type 2 diabetes, Diabetes Care., 27, 1496, 10.2337/diacare.27.6.1496
Austin, 1988, Low-density lipoprotein sub-class patterns and risk of myocardial infarction, JAMA., 260, 1917, 10.1001/jama.1988.03410130125037
Gardner, 1996, Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, JAMA., 276, 875, 10.1001/jama.1996.03540110029028
Williams, 2003, Smallest LDL particles are most strongly related to coronary disease progression in men, Arterioscler Thromb Vasc Biol., 23, 314, 10.1161/01.ATV.0000053385.64132.2D
Kuller, 2002, Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study, Arterioscler Thromb Vasc Biol., 22, 1175, 10.1161/01.ATV.0000022015.97341.3A
Mora, 2007, LDL particle sub-classes, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis., 192, 211, 10.1016/j.atherosclerosis.2006.05.007
Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk, Circulation., 82, 495, 10.1161/01.CIR.82.2.495
Pirwany, 2001, Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters, Clin Endocrinol (Oxf)., 54, 447, 10.1046/j.1365-2265.2001.01228.x
Garvey, 2003, Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance, Diabetes., 52, 453, 10.2337/diabetes.52.2.453
Goff, 2005, Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study, Metabolism., 54, 264, 10.1016/j.metabol.2004.09.002
Castelli, 1986, The triglyceride issue: a view from Framingham, Am Heart J., 112, 432, 10.1016/0002-8703(86)90296-6
Stampfer, 1996, A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction, JAMA., 276, 882, 10.1001/jama.1996.03540110036029
LaRosa, 1997, Triglycerides and coronary risk in women and the elderly, Arch Intern Med., 157, 961, 10.1001/archinte.1997.00440300051004
Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur Heart J, 19, M8
Austin, 1998, Hypertriglyceridemia as a cardiovascular risk factor, Am J Cardiol., 81, 7B, 10.1016/S0002-9149(98)00031-9
Jeppesen, 1998, Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study, (Erratum in: Circulation. 1998;97:1995). Circulation, 97, 1029
Onat, 2006, Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome, Int J Cardiol., 108, 89, 10.1016/j.ijcard.2005.06.056
Aznaouridis, 2007, Triglyceride level is associated with wave reflections and arterial stiffness in apparently healthy middle-aged men, Heart., 93, 613, 10.1136/hrt.2006.095554
Sarwar, 2007, Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies, Circulation., 115, 450, 10.1161/CIRCULATIONAHA.106.637793
Grundy, 1998, Consensus statement: Role of therapy with “statins” in patients with hypertriglyceridemia, Am J Cardiol., 81, 1B, 10.1016/S0002-9149(98)00030-7
Grundy, 1999, Hypertriglyceridemia, insulin resistance, and the metabolic syndrome, Am J Cardiol., 83, 25F, 10.1016/S0002-9149(99)00211-8
Kannel, 1979, Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study, Ann Intern Med., 90, 85, 10.7326/0003-4819-90-1-85
Assmann, 1992, Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study, Am J Cardiol., 70, 733, 10.1016/0002-9149(92)90550-I
Gotto, 1998, Triglyceride as a risk factor for coronary artery disease, Am J Cardiol., 82, 22Q, 10.1016/S0002-9149(98)00770-X
Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, JAMA., 298, 309, 10.1001/jama.298.3.309
Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA., 298, 299, 10.1001/jama.298.3.299
Malmstrom, 1997, Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM, Diabetologia., 40, 454, 10.1007/s001250050700
Daugherty, 1985, Aortic accumulation and plasma clearance of beta-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits, J Lipid Res., 26, 955, 10.1016/S0022-2275(20)34298-X
Chen, 1993, Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab., 76, 172
Rapp, 1994, Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque, Arterioscler Thromb., 14, 1767, 10.1161/01.ATV.14.11.1767
Ginsberg, 1998, Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1, Arterioscler Thromb Vasc Biol., 18, 441, 10.1161/01.ATV.18.3.441
Proctor, 1998, Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall--evidence that plaque cholesterol may be derived from post-prandial lipoproteins, Eur J Clin Invest., 28, 497, 10.1046/j.1365-2362.1998.00317.x
Kolovou, 2005, Clinical relevance of postprandial lipaemia, Curr Med Chem., 12, 1931, 10.2174/0929867054546609
Laufs, 2011, HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease, Program of the European Society of Cardiology Congress
Glueck, 2003, Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome, Metabolism., 52, 908, 10.1016/S0026-0495(03)00104-5
Christian, 2003, Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome, J Clin Endocrinol Metab., 88, 2562, 10.1210/jc.2003-030334
Talbott, 2004, Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J Clin Endocrinol Metab., 89, 5454, 10.1210/jc.2003-032237
Dahlgren, 1992, Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women, Acta Obstet Gynecol Scand., 71, 599, 10.3109/00016349209006227
Dahlgren, 1992, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones, Fertil Steril., 57, 505, 10.1016/S0015-0282(16)54892-4
Cibula, 2000, Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome, Hum Reprod., 15, 785, 10.1093/humrep/15.4.785
Scanu, 1992, Lipoprotein(a). A genetic risk factor for premature coronary heart disease, JAMA., 267, 3326, 10.1001/jama.1992.03480240088040
Marcovina, 1998, Lipoprotein(a) as a risk factor for coronary artery disease, JAMA., 82, 57U
Ridker, 1993, A prospective study of lipoprotein(a) and the risk of myocardial infarction, JAMA., 270, 2195, 10.1001/jama.1993.03510180065035
Schaefer, 1994, Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial, JAMA., 271, 999, 10.1001/jama.1994.03510370051031
Ridker, 1995, Plasma concentration of lipoprotein(a) and the risk of future stroke, JAMA., 273, 1269, 10.1001/jama.1995.03520400039041
Danesh, 2000, Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies, Circulation., 102, 1082, 10.1161/01.CIR.102.10.1082
Sharrett, 2001, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study, Circulation., 104, 1108, 10.1161/hc3501.095214
Luc, 2002, Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study, Atherosclerosis., 163, 377, 10.1016/S0021-9150(02)00026-6
van Wissen, 2003, Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia, Heart., 89, 893, 10.1136/heart.89.8.893
Gaw, 2005, PROSPER Study Group Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER), Atherosclerosis., 180, 381, 10.1016/j.atherosclerosis.2004.12.015
Suk Danik, 2006, Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women, JAMA., 296, 1363, 10.1001/jama.296.11.1363
Marcovina, 1993, Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans, The CARDIA study. Arterioscler Thromb., 13, 1037, 10.1161/01.ATV.13.7.1037
Berg, 1997, Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study, Clin Genet., 52, 254, 10.1111/j.1399-0004.1997.tb04342.x
Skurk, 2004, Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1, Int J Obes Relat Metab Disord., 28, 1357, 10.1038/sj.ijo.0802778
Mertens, 2005, Visceral fat as a determinant of fibrinolysis and hemostasis, Semin Vasc Med., 5, 48, 10.1055/s-2005-871741
Smith, 2005, Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke?, The Caerphilly Study. Circulation., 112, 3080, 10.1161/CIRCULATIONAHA.105.557132
Trost, 2006, Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes, Curr Diab Rep., 6, 47, 10.1007/s11892-006-0052-5
Stec, 2000, Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population, Circulation., 102, 1634, 10.1161/01.CIR.102.14.1634
Montalescot, 1998, Fibrinogen as a risk factor for coronary heart disease, Eur Heart J., 102, H11
Folsom, 1999, Fibrinogen and cardiovascular risk markers, Blood Coagul Fibrinolysis., 10, S13
Lowe, 1999, Clinical benefit of fibrinogen evaluation, Blood Coagul Fibrinolysis., 10, S87
Mehta, 1999, Should fibrinogen be measured routinely in patients with unstable coronary heart disease?, Blood Coagul Fibrinolysis., 10, S29
Ridker, 1999, Evaluating novel cardiovascular risk factors: can we better predict heart attacks?, Ann Intern Med., 130, 933, 10.7326/0003-4819-130-11-199906010-00018
Ridker, 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med., 336, 973, 10.1056/NEJM199704033361401
Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med., 342, 836, 10.1056/NEJM200003233421202
Ridker, 2001, High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation., 103, 1813, 10.1161/01.CIR.103.13.1813
Ridker, 1998, C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction, Circulation., 97, 2007, 10.1161/01.CIR.97.20.2007
Ballantyne, 2004, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Circulation., 109, 837, 10.1161/01.CIR.0000116763.91992.F1
Koenig, 2004, Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany, Circulation., 110, 1903, 10.1161/01.CIR.0000143377.53389.C8
Häkkinen, 1999, Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions, Arterioscler Thromb Vasc Biol., 19, 2909, 10.1161/01.ATV.19.12.2909
Laine, 1999, Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery, Circulation., 99, 361, 10.1161/01.CIR.99.3.361
MacPhee, 1999, Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor, Biochem J., 338, 479, 10.1042/bj3380479
Caslake, 2003, Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease, Curr Opin Lipidol., 14, 347, 10.1097/00041433-200308000-00002
Packard, 2000, Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group, N Engl J Med., 343, 1148, 10.1056/NEJM200010193431603
Corsetti, 2006, High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients, Clin Chem., 52, 1331, 10.1373/clinchem.2006.066845
Koenig, 2006, Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress, Arterioscler Thromb Vasc Biol., 26, 1586, 10.1161/01.ATV.0000222983.73369.c8
Andreotti, 1999, Homocysteine and arterial occlusive disease: a concise review, Cardiologia., 44, 341
Tyagi, 1999, Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix, Clin Exp Hypertens., 21, 181, 10.3109/10641969909068660
Nygård, 1997, Plasma homocysteine levels and mortality in patients with coronary artery disease, N Engl J Med., 337, 230, 10.1056/NEJM199707243370403
Cattaneo, 1999, Hyperhomocysteinemia, atherosclerosis and thrombosis, Thromb Haemost., 81, 165, 10.1055/s-0037-1614438
Maeda, 1989, Transient changes of serum lipoprotein(a) as an acute phase protein, Atherosclerosis., 78, 145, 10.1016/0021-9150(89)90218-9
Slunga, 1992, Lipoprotein(a) and acute-phase proteins in acute myocardial infarction, Scand J Clin Lab Invest., 52, 95, 10.3109/00365519209088771
Lindgren, 1995, Plasma homocysteine in the acute and convalescent phases after stroke, Stroke., 26, 795, 10.1161/01.STR.26.5.795
Egerton, 1996, Serial measures of plasma homocyst(e) ine after acute myocardial infarction, Am J Cardiol., 77, 759, 10.1016/S0002-9149(97)89213-2
Evans, 1997, Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial, Arterioscler Thromb Vasc Biol., 17, 1947, 10.1161/01.ATV.17.10.1947
Folsom, 1998, Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study, Circulation., 98, 204, 10.1161/01.CIR.98.3.204
Park, 2010, Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA, Am J Cardiol., 105, 1284, 10.1016/j.amjcard.2009.12.045
Veeranna, 2011, Homocysteine and reclassification of cardiovascular disease risk, J Am Coll Cardiol., 58, 1025, 10.1016/j.jacc.2011.05.028
Stanger, 2004, Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases, Z Kardiol., 93, 439, 10.1007/s00392-004-0075-3
Toole, 2004, Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial, JAMA., 291, 565, 10.1001/jama.291.5.565
Bønaa, 2006, Homocysteine lowering and cardiovascular events after acute myocardial infarction, N Engl J Med., 354, 1578, 10.1056/NEJMoa055227
Lonn, 2006, Homocysteine lowering with folic acid and B vitamins in vascular disease. (Erratum in: N Engl J Med. 2006;355:746), N Engl J Med., 354, 1567
Ray, 2007, Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial, Ann Intern Med., 146, 761, 10.7326/0003-4819-146-11-200706050-00157
2008, U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. Pediatric cardiovascular risk reduction initiative: background
Fang, 2000, Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey, JAMA., 283, 2404, 10.1001/jama.283.18.2404
Culleton, 1999, Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study, Ann Intern Med., 131, 7, 10.7326/0003-4819-131-1-199907060-00003
2002, National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am J Kidney Dis, 39, S1
Solomon, 2003, Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis, Circulation., 107, 1303, 10.1161/01.CIR.0000054612.26458.B2
Hak, 2009, Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study, Arthritis Rheum., 61, 1396, 10.1002/art.24537
Papadakis, 2009, High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity, Clin Exp Rheumatol., 27, 292
Grinspoon, 2008, State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. (Erratum in: Circulation. 2008;118:e109), Circulation, 118, 198, 10.1161/CIRCULATIONAHA.107.189622
Tuzcu, 2001, High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound, Circulation., 103, 2705, 10.1161/01.CIR.103.22.2705
Oren, 2003, Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study, Arch Intern Med., 163, 1787, 10.1001/archinte.163.15.1787
Paul, 2005, Cardiovascular risk profile of asymptomatic healthy young adults with increased femoral artery intima-media thickness: The Bogalusa Heart Study, Am J Med Sci., 330, 105, 10.1097/00000441-200509000-00001
Thavendiranathan, 2006, Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials, Arch Intern Med., 166, 2307, 10.1001/archinte.166.21.2307
Goff, 2006, Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium, Circulation., 113, 647, 10.1161/CIRCULATIONAHA.105.552737
Harris, 1989, Population screening for plasma cholesterol: community-based results from Atlanta, South Med J., 82, 1370, 10.1097/00007611-198911000-00010
Harris, 1989, Population screening for plasma cholesterol: community-based results from Miami, J Fla Med Assoc., 76, 853
Wynder, 1989, Population screening for plasma cholesterol: community-based results from Connecticut, Am Heart J., 117, 649, 10.1016/0002-8703(89)90741-2
Hoyert, 2006, Deaths: final data for 2003, Natl Vital Stat Rep., 54, 1
Thom, 2006, Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (Erratum in: Circulation. 2006;113:e696 and Circulation. 2006;114:e630), Circulation, 113, e85
Plehn, 1999, Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study, The Care Investigators. Circulation., 99, 216, 10.1161/01.CIR.99.2.216
Bugiardini, 2005, Angina with “normal” coronary arteries: a changing philosophy, JAMA., 293, 477, 10.1001/jama.293.4.477
Bugiardini, 2006, Women, ‘non-specific’ chest pain, and normal or near-normal coronary angiograms are not synonymous with favourable outcome, Eur Heart J., 27, 1387, 10.1093/eurheartj/ehi758
Nasir, 2004, Utility of stress testing and coronary calcification measurement for detection of coronary artery disease in women, Arch Intern Med., 164, 1610, 10.1001/archinte.164.15.1610
LaRosa, 1999, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA., 282, 2340, 10.1001/jama.282.24.2340
Davies, 1990, Atherogenesis and the coronary arteries of childhood, Int J Cardiol., 28, 283, 10.1016/0167-5273(90)90310-2
Joseph, 1993, Manifestations of coronary atherosclerosis in young trauma victims--an autopsy study, J Am Coll Cardiol., 22, 459, 10.1016/0735-1097(93)90050-B
McGill, 1998, Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group, Am J Cardiol., 82, 30T, 10.1016/S0002-9149(98)00720-6
Daniels, 2016, Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents Full Report
Newman, 1986, Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study, N Engl J Med., 314, 138, 10.1056/NEJM198601163140302
Klag, 1993, Serum cholesterol in young men and subsequent cardiovascular disease, N Engl J Med., 328, 313, 10.1056/NEJM199302043280504
Tracy, 1995, Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study, Am J Med Sci, 310, S37, 10.1097/00000441-199512000-00007
Li, 2003, Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study, JAMA., 290, 2271, 10.1001/jama.290.17.2271
Jacobson, 1988, The pediatrician’s role in atherosclerosis prevention, J Pediatr., 112, 836, 10.1016/S0022-3476(88)80709-1
1992, American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents, Pediatrics., 89, 525
Deckelbaum, 1996, Preventive nutrition in childhood: a rationale, Public Health Rev., 24, 105
Tonstad, 1997, A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits, Drug Saf., 16, 330, 10.2165/00002018-199716050-00004
Jacobson, 1998, Heart healthy diets for all children: no longer controversial, J Pediatr., 133, 1, 10.1016/S0022-3476(98)70167-2
Jacobson, 1998, Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention, Prev Med., 27, 775, 10.1006/pmed.1998.0356
Strong, 1999, Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study, JAMA., 281, 727, 10.1001/jama.281.8.727
Daniels, 2008, Committee on Nutrition. Lipid screening and cardiovascular health in childhood, Pediatrics., 122, 198, 10.1542/peds.2008-1349
Akerblom, 1992, Conclusions, guidelines and recommendations from the IUNS/WHO Workshop: nutrition in the pediatric age group and later cardiovascular disease, J Am Coll Nutr., 11, 1S, 10.1080/07315724.1992.10737973
Rifai, 1996, Failure of current guidelines for cholesterol screening in urban African-American adolescents, Pediatrics., 98, 383, 10.1542/peds.98.3.383
Kwiterovich, 1986, Biochemical, clinical, epidemiologic, genetic, and pathologic data in the pediatric age group relevant to the cholesterol hypothesis, Pediatrics., 78, 349, 10.1542/peds.78.2.349
Webber, 1991, Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study, Am J Epidemiol., 133, 884, 10.1093/oxfordjournals.aje.a115968
Kasim-Karakas, 1998, Dietary fat controversy: is it also applicable to children?, Am J Clin Nutr., 67, 1106, 10.1093/ajcn/67.6.1106
Arslanian, 1996, Insulin sensitivity, lipids, and body composition in childhood: is “syndrome X” present?, J Clin Endocrinol Metab., 81, 1058, 10.1210/jcem.81.3.8772576
Kavey, 2003, American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood, Circulation., 107, 1562, 10.1161/01.CIR.0000061521.15730.6E
Langsted, 2008, Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction, Circulation., 118, 2047, 10.1161/CIRCULATIONAHA.108.804146
Nauck, 2002, Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation, Clin Chem., 48, 236, 10.1093/clinchem/48.2.236
Lindsey, 2004, A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level, Pharmacotherapy., 24, 167, 10.1592/phco.24.2.167.33142
Hopkins, 2003, Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study, Circulation., 108, 519, 10.1161/01.CIR.0000081777.17879.85
Esteban-Salán, 2000, Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients, Clin Chem., 46, 1121, 10.1093/clinchem/46.8.1121
Xydakis, 2003, Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials, Curr Opin Cardiol., 18, 503, 10.1097/00001573-200311000-00012
Hsia, 2003, Non-HDL cholesterol: into the spotlight, Diabetes Care., 26, 240, 10.2337/diacare.26.1.240
Lu, 2003, Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study, Diabetes Care., 26, 16, 10.2337/diacare.26.1.16
Jialal, 2007, Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes, J Clin Endocrinol Metab., 92, 3136, 10.1210/jc.2007-0453
Bittner, 2002, Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI), Circulation., 106, 2537, 10.1161/01.CIR.0000038496.57570.06
Sniderman, 2005, Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is, Circulation., 112, 3366, 10.1161/CIRCULATIONAHA.105.583336
Stein, 2010, Carotid intima-media thickness, plaques, and cardiovascular disease risk: implications for preventive cardiology guidelines, J Am Coll Cardiol., 55, 1608, 10.1016/j.jacc.2009.11.073
Patsch, 1992, Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state, Arterioscler Thromb., 12, 1336, 10.1161/01.ATV.12.11.1336
Lefèbvre, 1998, The postprandial state and risk of cardiovascular disease, Diabet Med., 15, S63, 10.1002/(SICI)1096-9136(1998120)15:4+<S63::AID-DIA737>3.0.CO;2-7
Ooi, 1998, The atherogenic significance of an elevated plasma triglyceride level, Crit Rev Clin Lab Sci., 35, 489, 10.1080/10408369891234255
Boquist, 1999, Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men, Circulation., 100, 723, 10.1161/01.CIR.100.7.723
Karpe, 1999, Differences in post-prandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease, Metabolism., 48, 301, 10.1016/S0026-0495(99)90076-8
Karamanos, 2001, Maximal post-prandial triglyceride increase reflects post-prandial hypertriglyceridaemia and is associated with the insulin resistance syndrome, Diabet Med., 18, 32, 10.1046/j.1464-5491.2001.00386.x
Cohn, 2006, Postprandial lipemia and remnant lipoproteins, Clin Lab Med., 26, 773, 10.1016/j.cll.2006.07.003
Walldius, 2001, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, Lancet., 358, 2026, 10.1016/S0140-6736(01)07098-2
Shai, 2004, Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines, Circulation., 110, 2824, 10.1161/01.CIR.0000146339.57154.9B
Sattar, 2004, Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study, Circulation., 110, 2687, 10.1161/01.CIR.0000145660.60487.94
Sniderman, 2009, ApoB versus non-HDL-C: what to do when they disagree, Curr Atheroscler Rep., 11, 358, 10.1007/s11883-009-0054-2
Rodbard, 2008, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus (Erratum in Endocr Pract. ;14:802-803), Endocr Pract, 13, 1
Vodnala, 2012, Secondary causes of dyslipidemia, Am J Cardiol., 110, 823, 10.1016/j.amjcard.2012.04.062
Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med., 344, 1959, 10.1056/NEJM200106283442601
Miller, 2005, High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey, Arch Intern Med., 165, 2063, 10.1001/archinte.165.18.2063
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med., 359, 2195, 10.1056/NEJMoa0807646
Howard, 1993, Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound, ARIC Investigators. Stroke., 24, 1297, 10.1161/01.STR.24.9.1297
Lorenz, 2007, Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis, Circulation., 115, 459, 10.1161/CIRCULATIONAHA.106.628875
Blankenhorn, 1987, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. (Erratum in: JAMA. 1988;259:2698), JAMA, 257, 3233, 10.1001/jama.1987.03390230069027
Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med., 323, 1289, 10.1056/NEJM199011083231901
Blankenhorn, 1993, Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS), Ann Intern Med., 119, 969, 10.7326/0003-4819-119-10-199311150-00002
Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med., 345, 1583, 10.1056/NEJMoa011090
Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA., 291, 1071, 10.1001/jama.291.9.1071
Nissen, 2006, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial, JAMA., 295, 1556, 10.1001/jama.295.13.jpc60002
Schmermund, 2006, Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial, Circulation., 113, 427, 10.1161/CIRCULATIONAHA.105.568147
Taylor, 2006, The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3, Curr Med Res Opin., 22, 2243, 10.1185/030079906X148508
Crouse, 2007, Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial, JAMA., 297, 1344, 10.1001/jama.297.12.1344
Kastelein, 2008, Simvastatin with or without ezetimibe in familial hypercholesterolemia. (Erratum in: N Engl J Med. 2008;358:1977), N Engl J Med., 358, 1431, 10.1056/NEJMoa0800742
Nicholls, 2016, Effect of Evolocumab on Progression of Coronary Disease in Statin- Treated Patients: The GLAGOV Randomized Clinical Trial, JAMA., 316, 2373, 10.1001/jama.2016.16951
Wexler, 1996, Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group, Circulation., 94, 1175, 10.1161/01.CIR.94.5.1175
Bild, 2002, Multi-Ethnic Study of Atherosclerosis: objectives and design, Am J Epidemiol., 156, 871, 10.1093/aje/kwf113
Patel, 2015, Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: Results From Multiethnic Study of Atherosclerosis, Circ Cardiovasc Imaging., 8, 10.1161/CIRCIMAGING.115.003186
Yeboah, 2016, Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment, J Am Coll Cardiol., 67, 139, 10.1016/j.jacc.2015.10.058
Silverman, 2014, Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis, Eur Heart J., 35, 2232, 10.1093/eurheartj/eht508
Joshi, 2016, Coronary artery calcium predicts cardiovascular events in participants with a low lifetime risk of cardiovascular disease: The Multi- Ethnic Study of Atherosclerosis (MESA), Atherosclerosis., 246, 367, 10.1016/j.atherosclerosis.2016.01.017
Blaha, 2016, Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: The Multi- Ethnic Study of Atherosclerosis (MESA), Circulation., 133, 849, 10.1161/CIRCULATIONAHA.115.018524
Haralambos, 2016, Diagnostic scoring for familial hypercholesterolaemia in practice, Curr Opin Lipidol., 27, 367, 10.1097/MOL.0000000000000325
Castelli, 1988, Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study, Can J Cardiol, 4, 5A
Bass, 1993, Plasma lipoprotein levels as predictors of cardiovascular death in women, Arch Intern Med., 153, 2209, 10.1001/archinte.1993.00410190045006
Rubins, 1999, Gemfibozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med., 341, 410, 10.1056/NEJM199908053410604
Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA., 285, 1585, 10.1001/jama.285.12.1585
Genest, 1995, Clustering of cardiovascular risk factors: targeting high-risk individuals, Am J Cardiol., 76, 8A, 10.1016/S0002-9149(05)80010-4
Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med., 317, 1237, 10.1056/NEJM198711123172001
Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. (Erratum in: Lancet. 2006;368:1415 and Lancet. 2006;368:1420), Lancet, 366, 1849
Tenkanen, 2006, Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study, Arch Intern Med., 166, 743, 10.1001/archinte.166.7.743
Kris-Etherton, 2000, Is there an optimal diet for the hypertriglyceridemic patient?, J Cardiovasc Risk., 7, 333, 10.1177/204748730000700506
Grundy, 2002, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial, Arch Intern Med., 162, 1568, 10.1001/archinte.162.14.1568
Goldberg, 2004, A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women, Am J Cardiol., 94, 121, 10.1016/j.amjcard.2004.03.042
Ratner, 2005, Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program, Diabetes Care., 28, 888, 10.2337/diacare.28.4.888
Ahead Look Research Group, 2007, Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial, Diabetes Care., 30, 1374, 10.2337/dc07-0048
Harris, 1990, Fish oils in hypertriglyceridemia: a dose-response study, Am J Clin Nutr., 51, 399, 10.1093/ajcn/51.3.399
Davidson, 2007, Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study, Clin Ther., 29, 1354, 10.1016/j.clinthera.2007.07.018
Balk
Brunzell, 1976, Myocardial infarction in the familial forms of hypertriglyceridemia, Metabolism., 25, 313, 10.1016/0026-0495(76)90089-5
Austin, 2000, Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study, Circulation., 101, 2777, 10.1161/01.CIR.101.24.2777
Hulley, 1980, Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease, N Engl J Med., 302, 1383, 10.1056/NEJM198006193022503
Santamarina-Fojo, 1991, The familial hyper-chylomicronemia syndrome. New insights into underlying genetic defects, JAMA., 265, 904, 10.1001/jama.1991.03460070086049
Rader, 1999, Role of fibrates in the management of hypertriglyceridemia, Am J Cardiol., 83, 30F, 10.1016/S0002-9149(99)00270-2
Yuan, 2007, Hypertriglyceridemia: its etiology, effects and treatment, CMAJ., 176, 1113, 10.1503/cmaj.060963
Plaisance, 2006, Physical activity and high-sensitivity C-reactive protein, Sports Med., 36, 443, 10.2165/00007256-200636050-00006
Paffenbarger, 1993, The association of changes in physical-activity level and other lifestyle characteristics with mortality among men, N Engl J Med., 328, 538, 10.1056/NEJM199302253280804
Pate, 1995, Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine, JAMA., 273, 402, 10.1001/jama.1995.03520290054029
Manson, 1999, A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women, N Engl J Med., 341, 650, 10.1056/NEJM199908263410904
Krauss, 2000, AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association, Circulation., 102, 2284, 10.1161/01.CIR.102.18.2284
Kesaniemi, 2001, Dose-response issues concerning physical activity and health: an evidence-based symposium, Med Sci Sports Exerc., 33, S351, 10.1097/00005768-200106001-00003
Manson, 2002, Walking compared with vigorous exercise for the prevention of cardiovascular events in women, N Engl J Med., 347, 716, 10.1056/NEJMoa021067
Gregg, 2003, Relationship of changes in physical activity and mortality among older women, JAMA., 289, 2379, 10.1001/jama.289.18.2379
Haskell, 2007, Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association, Circulation., 116, 1081, 10.1161/CIRCULATIONAHA.107.185649
Jakicic, 1995, Prescribing exercise in multiple short bouts versus one continuous bout: effects on adherence, cardiorespiratory fitness, and weight loss in overweight women, Int J Obes Relat Metab Disord., 19, 893
Donnelly, 2000, The effects of 18 months of intermittent vs. continuous exercise on aerobic capacity, body weight and composition, and metabolic fitness in previously sedentary, moderately obese females, Int J Obes Relat Metab Disord., 24, 566, 10.1038/sj.ijo.0801198
Murphy, 2002, Accumulating brisk walking for fitness, cardiovascular risk, and psychological health, Med Sci Sports Exerc., 34, 1468, 10.1097/00005768-200209000-00011
Mayer-Davis, 1998, Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study, JAMA., 279, 669, 10.1001/jama.279.9.669
Levinger, 2007, The effect of resistance training on functional capacity and quality of life in individuals with high and low numbers of metabolic risk factors, Diabetes Care., 30, 2205, 10.2337/dc07-0841
Wijndaele, 2007, Muscular strength, aerobic fitness, and metabolic syndrome risk in Flemish Adults, Med Sci Sports Exerc., 39, 233, 10.1249/01.mss.0000247003.32589.a6
Kelley, 2009, Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials, Prev Med., 48, 9, 10.1016/j.ypmed.2008.10.010
Kirk, 2003, Increasing physical activity in people with type 2 diabetes, Diabetes Care., 26, 1186, 10.2337/diacare.26.4.1186
Hughes, 2007, Effect of an exercise consultation on maintenance of physical activity after completion of phase III exercise-based cardiac rehabilitation, Eur J Cardiovasc Prev Rehabil., 14, 114, 10.1097/HJR.0b013e3280116485
Isaacs, 2007, Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only, Health Technol Assess., 11, 1, 10.3310/hta11100
Kirk, 2007, Strategies to enhance compliance to physical activity for patients with insulin resistance, Appl Physiol Nutr Metab., 32, 549, 10.1139/H07-023
Mensink, 1992, Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials, Arterioscler Thromb., 12, 911, 10.1161/01.ATV.12.8.911
Garg, 1992, Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM, Diabetes., 41, 1278, 10.2337/diab.41.10.1278
Garg, 1998, High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis, Am J Clin Nutr., 67, 577S, 10.1093/ajcn/67.3.577S
Kris-Etherton, 1999, High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations, Am J Clin Nutr., 70, 1009, 10.1093/ajcn/70.6.1009
Mozaffarian, 2006, Trans fatty acids and cardiovascular disease, N Engl J Med., 354, 1601, 10.1056/NEJMra054035
Singh, 1992, Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up, BMJ., 304, 1015, 10.1136/bmj.304.6833.1015
Krauss, 1996, Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association, Circulation., 94, 1795, 10.1161/01.CIR.94.7.1795
Bucher, 1999, Systematic review on the risk and benefit of different cholesterol-lowering interventions, Arterioscler Thromb Vasc Biol., 19, 187, 10.1161/01.ATV.19.2.187
de Lorgeril, 1999, Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study, Circulation., 99, 779, 10.1161/01.CIR.99.6.779
2000, Diabetes Care, 23, S43
Hu, 2000, Prospective study of major dietary patterns and risk of coronary heart disease in men, Am J Clin Nutr., 72, 912, 10.1093/ajcn/72.4.912
Bazzano, 2002, Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, Am J Clin Nutr., 76, 93, 10.1093/ajcn/76.1.93
Estruch, 2013, Primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med., 368, 1279, 10.1056/NEJMoa1200303
Havel, 1995, Management of primary hyperlipidemia. (Erratum in: N Engl J Med. 1995;333:467), N Engl J Med., 332, 1491, 10.1056/NEJM199506013322207
Van Horn, 1997, Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association, Circulation., 95, 2701, 10.1161/01.CIR.95.12.2701
Kirby, 1981, Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men, Am J Clin Nutr., 34, 824, 10.1093/ajcn/34.5.824
Anderson, 1984, Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men, Am J Clin Nutr., 40, 1146, 10.1093/ajcn/40.6.1146
Anderson, 1990, Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans, Am J Clin Nutr., 51, 1013, 10.1093/ajcn/51.6.1013
Anderson, 1990, Oat-bran cereal lowers serum total and LDL cholesterol in hypercholesterolemic men, Am J Clin Nutr., 52, 495, 10.1093/ajcn/52.3.495
Anderson, 1991, Lipid responses of hypercholesterolemic men to oat-bran and wheat-bran intake, Am J Clin Nutr., 54, 678, 10.1093/ajcn/54.4.678
Gylling, 1999, Cholesterol reduction by different plant stanol mixtures and with variable fat intake, Metabolism., 48, 575, 10.1016/S0026-0495(99)90053-7
Gylling, 1999, Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population, J Lipid Res., 40, 593, 10.1016/S0022-2275(20)32138-6
Hallikainen, 1999, Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects, Am J Clin Nutr., 69, 403, 10.1093/ajcn/69.3.403
Miettinen, 1999, Regulation of cholesterol metabolism by dietary plant sterols, Curr Opin Lipidol., 10, 9, 10.1097/00041433-199902000-00003
Grundy, 1986, Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol, N Engl J Med., 314, 745, 10.1056/NEJM198603203141204
Mensink, 1987, Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women, Lancet., 1, 122, 10.1016/S0140-6736(87)91965-9
Chen, 1995, Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM?, Diabetes Care., 18, 10, 10.2337/diacare.18.1.10
Knopp, 1997, Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men, The Dietary Alternatives Study. JAMA., 278, 1509
Katan, 1997, Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets, N Engl J Med., 337, 563
Harris, 1997, n-3 fatty acids and serum lipoproteins: human studies, Am J Clin Nutr., 65, 1645S, 10.1093/ajcn/65.5.1645S
Harris, 1999, Nonpharmacologic treatment of hypertriglyceridemia: focus on fish oils, Clin Cardiol., 22, II40, 10.1002/clc.4960221408
Mozaffarian, 2006, Fish intake, contaminants, and human health: evaluating the risks and the benefits. (Erratum in: JAMA. 2007;297:590), JAMA, 296, 1885, 10.1001/jama.296.15.1885
Mozaffarian, 2008, Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death, Am J Clin Nutr., 87, 1991S, 10.1093/ajcn/87.6.1991S
Heydari, 2016, Effect of Omega-3 acid ethyl esters on left ventricular Remodeling after acute myocardial infarction: The OMEGA-REMODEL Randomized Clinical Trial, Circulation., 134, 378, 10.1161/CIRCULATIONAHA.115.019949
Watson, 2009, Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease, Am J Cardiol., 104, 1052, 10.1016/j.amjcard.2009.05.055
Walden, 1997, Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men, Arterioscler Thromb Vasc Biol., 17, 375, 10.1161/01.ATV.17.2.375
Ornish, 1998, Intensive lifestyle changes for reversal of coronary heart disease. (Erratum in: JAMA. 1999;281:1380), JAMA, 280, 2001, 10.1001/jama.280.23.2001
Gardner, 2007, Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight pre-menopausal women: the A TO Z Weight Loss Study: a randomized trial. (Erratum in: JAMA. 2007;298:178), JAMA, 297, 969, 10.1001/jama.297.9.969
Key, 2003, Mortality in British vegetarians: review and preliminary results from EPIC-Oxford, Am J Clin Nutr., 78, 533S, 10.1093/ajcn/78.3.533S
Sacks, 1975, Plasma lipids and lipoproteins in vegetarians and controls, N Engl J Med., 292, 1148, 10.1056/NEJM197505292922203
Sacks, 1981, Effect of ingestion of meat on plasma cholesterol of vegetarians, JAMA., 246, 640, 10.1001/jama.1981.03320060042020
Schaefer, 1993, New recommendations for the diagnosis and treatment of plasma lipid abnormalities, Nutr Rev., 51, 246, 10.1111/j.1753-4887.1993.tb03115.x
Dreon, 1994, Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men, FASEB J., 8, 121, 10.1096/fasebj.8.1.8299884
Dreon, 1997, LDL subclass patterns and lipoprotein response to a low-fat, high-carbohydrate diet in women, Arterioscler Thromb Vasc Biol., 17, 707, 10.1161/01.ATV.17.4.707
Borgia, 1998, Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease, Angiology., 49, 339, 10.1177/000331979804900502
Caranti, 2007, Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents, Metabolism., 56, 1293, 10.1016/j.metabol.2007.05.004
Kelishadi, 2010, Effects of a lifestyle modification trial among phenotypically obese metabolically normal and phenotypically obese metabolically abnormal adolescents in comparison with phenotypically normal metabolically obese adolescents, Matern Child Nutr., 6, 275
Savoye, 2011, Long-term results of an obesity program in an ethnically diverse pediatric population, Pediatrics., 127, 402, 10.1542/peds.2010-0697
Newman, 1990, The case against childhood cholesterol screening, JAMA., 264, 3039, 10.1001/jama.1990.03450230075032
Budow, 1989, The effect of dietary therapy on growth in hyperlipidemic children and adolescents: a prospective clinical trial [Abstract], Pediatr Res, 25, 22A
O’Connell, 1989, Growth of vegetarian children: The Farm Study, Pediatrics., 84, 475, 10.1542/peds.84.3.475
Shea, 1993, Is there a relationship between dietary fat and stature or growth in children three to five years of age?, Pediatrics., 92, 579, 10.1542/peds.92.4.579
Boulton, 1995, Effects of differences in dietary fat on growth, energy and nutrient intake from infancy to eight years of age, Acta Paediatr, 84, 146, 10.1111/j.1651-2227.1995.tb13597.x
Copperman, 1995, Nutrient quality of fat-and cholesterol-modified diets of children with hyperlipidemia, Arch Pediatr Adolesc Med., 149, 333, 10.1001/archpedi.1995.02170150113022
Lapinleimu, 1995, Prospective randomised trial in 1062 infants of diet low in saturated fat and cholesterol, Lancet., 345, 471, 10.1016/S0140-6736(95)90580-4
Niinikoski, 1996, Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project, Circulation., 94, 1386, 10.1161/01.CIR.94.6.1386
Niinikoski, 1997, Regulation of growth of 7-to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial, Pediatrics., 100, 810, 10.1542/peds.100.5.810
Obarzanek, 1997, Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC), Pediatrics., 100, 51, 10.1542/peds.100.1.51
Tershakovec, 1998, Growth of hypercholesterolemic children completing physician-initiated low-fat dietary intervention, J Pediatr., 133, 28, 10.1016/S0022-3476(98)70173-8
Mietus-Snyder, 1993, Effects of nutritional counseling on lipoprotein levels in a pediatric lipid clinic, Am J Dis Child., 147, 378
Kwiterovich, 1994, Dyslipoproteinemia and other risk factors for atherosclerosis in children and adolescents, Atherosclerosis., 108, S55, 10.1016/0021-9150(94)90153-8
1995, Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC), JAMA, 273, 1429, 10.1001/jama.1995.03520420045036
Hennermann, 1998, Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy, Eur J Pediatr., 157, 912, 10.1007/s004310050966
Starc, 1998, Greater dietary intake of simple carbohydrate is associated with lower concentrations of high-density-lipoprotein cholesterol in hypercholesterolemic children, Am J Clin Nutr., 67, 1147, 10.1093/ajcn/67.6.1147
Goren, 1991, Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy, Pediatrics., 88, 265, 10.1542/peds.88.2.265
Gidding, 2005, Dietary recommendations for children and adolescents: a guide for practitioner: consensus statement from the American Heart Association. (Errata in: Circulation. 2005;112:2375 and Circulation. 2006;113:e857), Circulation, 112, 2061, 10.1161/CIRCULATIONAHA.105.169251
Roberts, 2007, Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors, Atherosclerosis., 191, 98, 10.1016/j.atherosclerosis.2006.09.011
Tammi, 2002, Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters in children: the STRIP study. Special Turku Coronary Risk Factor Intervention Project, Acta Paediatr., 91, 1155, 10.1111/j.1651-2227.2002.tb00121.x
Lichtenstein, 2001, AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association, Circulation., 103, 1177, 10.1161/01.CIR.103.8.1177
Porkka, 1996, Serum lipoproteins in children and young adults: determinants and treatment strategies, Curr Opin Lipidol., 7, 183, 10.1097/00041433-199608000-00002
Raitakari, 1995, Clustering of risk habits in young adults. The Cardiovascular Risk in Young Finns Study, Am J Epidemiol., 142, 36, 10.1093/oxfordjournals.aje.a117543
Fiore, 2008
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med., 333, 1301, 10.1056/NEJM199511163332001
Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med., 335, 1001, 10.1056/NEJM199610033351401
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA., 279, 1615, 10.1001/jama.279.20.1615
Brugts, 2009, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials, BMJ., 338, b2376, 10.1136/bmj.b2376
Taylor, 2011, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev., 1
Ridker, 2009, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, Lancet., 373, 1175, 10.1016/S0140-6736(09)60447-5
Cannon, 2006, Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy, J Am Coll Cardiol., 48, 438, 10.1016/j.jacc.2006.04.070
Rifkind, 1986, The Lipid Research Clinics Coronary Primary Prevention Trial, Drugs., 31, 53, 10.2165/00003495-198600311-00010
Ridker, 2007, Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein, Am J Cardiol., 100, 1659, 10.1016/j.amjcard.2007.09.072
Brown, 1995, Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study, Ann N Y Acad Sci., 748, 407, 10.1111/j.1749-6632.1994.tb17337.x
Ericsson, 1996, Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients, Lancet., 347, 849, 10.1016/S0140-6736(96)91343-4
McCormick, 1997, Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT), Am J Cardiol., 80, 1130, 10.1016/S0002-9149(97)00627-9
2000, Benzafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, Circulation., 102, 21, 10.1161/01.CIR.102.1.21
Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, Curr Med Res Opin., 18, 220, 10.1185/030079902125000787
de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, JAMA., 292, 1307, 10.1001/jama.292.11.1307
Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955
Arbel, 2016, Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial, Cardiovasc Diabetol., 15, 10.1186/s12933-016-0332-6
Sabatine, 2017, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med., 10.1056/NEJMoa1615664
Schulze, 2004, C-reactive protein and incident cardiovascular events among men with diabetes, Diabetes Care., 27, 889, 10.2337/diacare.27.4.889
Superko, 1997
White, 1998, Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials, Am J Med., 105, 63S, 10.1016/S0002-9343(98)00214-9
Campeau, 1999, Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial, Post CABG Trial Investigators. Circulation., 99, 3241
Dotani, 2000, Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting, Am J Cardiol., 86, 1128, 10.1016/S0002-9149(00)01172-3
Knatterud, 2000, Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial, Post CABG Investigators. Circulation., 102, 157
Brull, 2001, Statin therapy and the acute inflammatory response after coronary artery bypass grafting, Am J Cardiol., 88, 431, 10.1016/S0002-9149(01)01696-4
Pan, 2004, Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery, Circulation., 110, 1145, 10.1161/01.CIR.0000138316.24048.08
Chello, 2006, Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery, Crit Care Med., 34, 660, 10.1097/01.CCM.0000201407.89977.EA
Marín, 2006, Statins and post-operative risk of atrial fibrillation following coronary artery bypass grafting, Am J Cardiol., 97, 55, 10.1016/j.amjcard.2005.07.124
Albert, 2001, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study, JAMA, 286, 64, 10.1001/jama.286.1.64
McFarlane, 2002, Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond, J Clin Endocrinol Metab., 87, 1451, 10.1210/jcem.87.4.8412
Kinlay, 2003, High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study, Circulation., 108, 1560, 10.1161/01.CIR.0000091404.09558.AF
Economides, 2004, The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes, J Clin Endocrinol Metab., 89, 740, 10.1210/jc.2003-031116
Liao, 2005, Pleiotropic effects of statins, Annu Rev Pharmacol Toxicol., 45, 89, 10.1146/annurev.pharmtox.45.120403.095748
Macin, 2005, Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study, Am Heart J., 149, 451, 10.1016/j.ahj.2004.07.041
Morrow, 2006, Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastatto-Zocor Trial, Circulation., 114, 281, 10.1161/CIRCULATIONAHA.106.628909
Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, JAMA., 285, 1711, 10.1001/jama.285.13.1711
Wenger, 2007, Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease, Ann Intern Med., 147, 1, 10.7326/0003-4819-147-1-200707030-00002
Olsson, 2007, Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study), Am J Cardiol., 99, 632, 10.1016/j.amjcard.2006.09.111
Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet, 385, 1397, 10.1016/S0140-6736(14)61368-4
Tikkanen, 1996, Statins: within-group comparisons, statin escape and combination therapy, Curr Opin Lipidol., 7, 385, 10.1097/00041433-199612000-00008
Davignon, 1998, Advances in drug treatment of dyslipidemia: focus on atorvastatin, Can J Cardiol, 14, 28B
Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet., 377, 2181, 10.1016/S0140-6736(11)60739-3
Davidson, 2001, Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia, Clin Cardiol., 24, 467, 10.1002/clc.4960240610
Hunninghake, 2001, Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively, Atherosclerosis., 158, 407, 10.1016/S0021-9150(01)00437-3
Knapp, 2001, Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia, Am J Med., 110, 352, 10.1016/S0002-9343(01)00638-6
Ballantyne, 2004, Efficacy and safety of rosuvastatin alone and in combination with chole styramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial, Clin Ther., 26, 1855, 10.1016/j.clinthera.2004.11.001
Goldberg, 2004, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial, Mayo Clin Proc., 79, 620, 10.4065/79.5.620
2012, Lescol (fluvastatin sodium) [prescribing information
2014, Mevacor (lovastatin) [prescribing information]
2015, Lipitor (atorvastatin calcium) [prescribing information].
2015, Zocor (simvastatin) [prescribing information]
2016, Crestor (rosuvastatin calcium) [prescribing information]
Mampuya, 2013, Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience, Am Heart J., 166, 597, 10.1016/j.ahj.2013.06.004
2011, NHLBI Communications Office. NIH stops clinical trial on combination cholesterol
Athyros, 1995, Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia, Coron Artery Dis., 6, 25
Avellone, 1995, Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia, Blood Coagul Fibrinolysis., 6, 543, 10.1097/00001721-199509000-00007
Bröijersen, 1996, Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels, Arterioscler Thromb Vasc Biol., 16, 511, 10.1161/01.ATV.16.4.511
Bröijersén, 1996, Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII, Thromb Haemost., 76, 171, 10.1055/s-0038-1650548
Kockx, 1997, Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients, Thromb Haemost., 78, 1167, 10.1055/s-0038-1657709
Durrington, 1998, Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia, Atherosclerosis., 138, 217, 10.1016/S0021-9150(98)00003-3
Guyton, 2000, Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol, Niaspan-Gemfibrozil Study Group. Arch Intern Med., 160, 1177, 10.1001/archinte.160.8.1177
Aguilar-Salinas, 2001, Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study, Metabolism., 50, 729, 10.1053/meta.2001.23308
Bays, 2001, Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. (Erratum in: Clin Ther. 2001;23:1601), Clin Ther., 23, 1209, 10.1016/S0149-2918(01)80102-8
Westphal, 2001, Effects of fenofibrate and gemfibrozil on plasma homocysteine, Lancet., 358, 39, 10.1016/S0140-6736(00)05271-5
Dujovne, 2002, Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. (Erratum in: Am J Cardiol. 2003;91:1399), Am J Cardiol., 90, 109
Gagne, 2002, Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia, Am J Cardiol., 90, 1084, 10.1016/S0002-9149(02)02774-1
Hottelart, 2002, Fenofibrate increases creatininemia by increasing metabolic production of creatinine, Nephron., 92, 536, 10.1159/000064083
Insua, 2002, Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study, Endocr Pract., 8, 96, 10.4158/EP.8.2.96
Syvänne, 2004, Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis, Atherosclerosis., 172, 267, 10.1016/j.atherosclerosis.2003.10.003
Brohet, 2005, LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia, Curr Med Res Opin., 21, 571, 10.1185/030079905X382004
Farnier, 2005, Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia, Eur Heart J., 26, 897, 10.1093/eurheartj/ehi231
Denke, 2006, Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome, Diab Vasc Dis Res., 3, 93, 10.3132/dvdr.2006.020
McKenney, 2006, Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia, J Am Coll Cardiol., 47, 1584, 10.1016/j.jacc.2005.11.072
Davidson, 2007, Safety considerations with fibrate therapy, Am J Cardiol., 99, 3C, 10.1016/j.amjcard.2006.11.016
Zieve, 2007, Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes, Clin Ther., 29, 74, 10.1016/j.clinthera.2007.01.003
2010, Lopid (gemfibrozil) [prescribing information]
2010, Tricor (fenofibrate) [prescribing information]
2016, American Diabetes Association. Data from the 2011 National Diabetes Fact Sheet (released January 26, 2011)
Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis, JAMA., 305, 2556, 10.1001/jama.2011.860
2012, Juxtapid (lomitapide) [prescribing information]
Knopp, 2013, Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies, Int J Clin Pract., 57, 363
2013, Livalo (pitavastatin) [prescribing information]
2013, Zetia (ezetimibe) [prescribing information]
2014, Colestid (colestipol hydrochloride) [prescribing information]
2014, WelChol (colesevelam hydrochloride) [prescribing information]
2015, Lovaza (omega-3-acid ethyl esters) [prescribing information]
2015, Niaspan (niacin extended-release) [prescribing information]
2015, Praluent (alirocumab) prescribing information
2015, Prevalite (cholestyramine for oral suspension, USP) [prescribing information]
2016, Kynamro (mipomersen sodium) Injection [prescribing information]
2016, Pravachol (pravastatin sodium) [prescribing information]
2016, Repatha (evolocumab) [prescribing information]
2016, Trilipix (fenofibric acid) [prescribing information]
2016, Vascepa (icosapent ethyl) [prescribing information]
Lennernäs, 1997, Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors, Similarities and differences. Clin Pharmacokinet., 32, 403, 10.2165/00003088-199732050-00005
Guerin, 2002, Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux, Atherosclerosis., 163, 287, 10.1016/S0021-9150(02)00037-0
Pontrelli, 2002, Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes, Metabolism., 51, 334, 10.1053/meta.2002.30510
Sakabe, 2003, Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients, Circ J., 67, 866, 10.1253/circj.67.866
van Tits, 2004, Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia, J Investig Med., 52, 177
Baldassarre, 2005, Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin, Int J Cardiol., 104, 338, 10.1016/j.ijcard.2005.01.006
Bevilacqua, 2005, Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes, Adv Ther., 22, 527, 10.1007/BF02849947
Sirtori, 2005, Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin, Nutr Metab Cardiovasc Dis., 15, 47, 10.1016/j.numecd.2004.08.001
Miller, 2006, The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study, Curr Med Res Opin., 22, 343, 10.1185/030079906X80521
Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X
Ford, 2007, Long-term follow-up of the West of Scotland Coronary Prevention Study, N Engl J Med., 357, 1477, 10.1056/NEJMoa065994
Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). (Erratum in: Am J Cardiol. 1998;82:128), Am J Cardiol., 81, 582, 10.1016/S0002-9149(97)00965-X
Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial), Am J Cardiol., 92, 152, 10.1016/S0002-9149(03)00530-7
Stein, 2008, Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?, J Am Coll Cardiol., 52, 2206, 10.1016/j.jacc.2008.11.002
Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease, N Engl J Med., 365, 2078, 10.1056/NEJMoa1110874
Kashani, 2006, Risks associated with statin therapy: a systematic overview of randomized clinical trials, Circulation., 114, 2788, 10.1161/CIRCULATIONAHA.106.624890
Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study, Cardiovasc Drugs Ther., 19, 403, 10.1007/s10557-005-5686-z
Harper, 2007, The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis, Curr Opin Lipidol., 18, 401, 10.1097/MOL.0b013e32825a6773
Scott, 1991, Simvastatin and side effects, N Z Med J., 104, 493
Ballantyne, 2004, Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia, Int J Clin Pract., 58, 653, 10.1111/j.1368-5031.2004.00278.x
Masana, 2005, Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study, Clin Ther., 27, 174, 10.1016/j.clinthera.2005.02.011
Graham, 2004, Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA., 292, 2585, 10.1001/jama.292.21.2585
Cederberg, 2015, Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort, Diabetologia., 58, 1109, 10.1007/s00125-015-3528-5
Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study, BMJ., 346, f2610, 10.1136/bmj.f2610
Jen, 1997, Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study, Zhonghua Yi Xue Za Zhi (Taipei)., 59, 217
Staels, 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation., 98, 2088, 10.1161/01.CIR.98.19.2088
Frick, 1997, Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group, Circulation., 96, 2137, 10.1161/01.CIR.96.7.2137
Robins, 2003, Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT), Diabetes Care., 26, 1513, 10.2337/diacare.26.5.1513
Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus. (Erratum in: N Engl J Med. 2010;362:1748), N Engl J Med., 362, 1563
Folsom, 2008, Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA), Arch Intern Med., 168, 1333, 10.1001/archinte.168.12.1333
Giral, 2001, Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia, Atherosclerosis., 154, 421, 10.1016/S0021-9150(00)00474-3
Mayer, 2006, Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates, Physiol Res., 55, 475, 10.33549/physiolres.930856
Koh, 2005, Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia, Diabetes Care., 28, 1419, 10.2337/diacare.28.6.1419
Saklamaz, 2005, The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia, Metabolism., 54, 677, 10.1016/j.metabol.2004.12.012
Wu, 2007, Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate, Ann Clin Lab Sci., 37, 158
McKenney, 2004, New perspectives on the use of niacin in the treatment of lipid disorders, Arch Intern Med., 164, 697, 10.1001/archinte.164.7.697
Meyers, 2003, Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia, Ann Intern Med, 139, 996, 10.7326/0003-4819-139-12-200312160-00009
Morgan, 1996, Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial, J Cardiovasc Pharmacol Ther., 1, 195, 10.1177/107424849600100302
Guyton, 1998, Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia, Am J Cardiol., 82, 737, 10.1016/S0002-9149(98)00448-2
Pan, 2002, Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes, Diabetes Obes Metab., 4, 255, 10.1046/j.1463-1326.2002.00205.x
Pan, 2002, Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes, Metabolism., 51, 1120, 10.1053/meta.2002.34701
Elam, 2000, Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial, Arterial Disease Multiple Intervention Trial. JAMA., 284, 1263
Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, J Am Coll Cardiol., 8, 1245, 10.1016/S0735-1097(86)80293-5
Blankenhorn, 1987, The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results, Control Clin Trials., 8, 356, 10.1016/0197-2456(87)90156-5
Canner, 2005, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project), Am J Cardiol., 95, 254, 10.1016/j.amjcard.2004.09.013
Cashin-Hemphill, 1990, Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up, JAMA., 264, 3013, 10.1001/jama.1990.03450230049028
Vittone, 2007, Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS), J Clin Lipidol., 1, 203, 10.1016/j.jacl.2007.05.003
Shepherd, 1989, Mechanism of action of bile acid sequestrants and other lipid-lowering drugs, Cardiology., 76, 65, 10.1159/000174548
Hunninghake, 1981, Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia, Metabolism., 30, 605, 10.1016/0026-0495(81)90140-2
Brensike, 1984, Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study, Circulation., 69, 313, 10.1161/01.CIR.69.2.313
Superko, 1992, Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia, Am J Cardiol., 70, 135, 10.1016/0002-9149(92)91264-5
Lyons, 1994, Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia, Br J Clin Pharmacol., 37, 59, 10.1111/j.1365-2125.1994.tb04239.x
Davidson, 1999, Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects, Arch Intern Med., 159, 1893, 10.1001/archinte.159.16.1893
Insull, 2006, Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review, South Med J., 99, 257, 10.1097/01.smj.0000208120.73327.db
Probstfield, 1991, The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications, Eur J Clin Pharmacol., 40, S69, 10.1007/BF03216294
Fonseca, 2008, Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy, Diabetes Care., 31, 1479, 10.2337/dc08-0283
Bays, 2008, Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects, Arch Intern Med., 168, 1975, 10.1001/archinte.168.18.1975
Andrade, 1995, Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?, N Engl J Med., 332, 1125, 10.1056/NEJM199504273321703
Avorn, 1998, Persistence of use of lipid-lowering medications: a cross-national study, JAMA., 279, 1458, 10.1001/jama.279.18.1458
Insull, 2001, Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial, Mayo Clin Proc., 76, 971, 10.4065/76.10.971
Altmann, 2004, Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption, Science., 303, 1201, 10.1126/science.1093131
Phan, 2012, Ezetimibe therapy: mechanism of action and clinical update, Vasc Health Risk Manag., 8, 415
Masuda, 2009, Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia, Eur J Clin Invest., 39, 689, 10.1111/j.1365-2362.2009.02163.x
Cruz-Fernández, 2005, Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease, Int J Clin Pract., 59, 619, 10.1111/j.1368-5031.2005.00565.x
Ballantyne, 2005, Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. (Erratum in: Am Heart J. 2005;149:882), Am Heart J., 149, 464, 10.1016/j.ahj.2004.11.023
Catapano, 2006, Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients, Curr Med Res Opin., 22, 2041, 10.1185/030079906X132721
Jellinger, 2008, Looking beyond the ezetimibe controversy, Int Med News., 41, 9, 10.1016/S1097-8690(08)70183-5
Schering-Plough, 2007
Rossebo, 2008, Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N Engl J Med., 359, 1343, 10.1056/NEJMoa0804602
Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med., 372, 1489, 10.1056/NEJMoa1501031
Stoekenbroek, 2015, PCSK9 inhibition: the way forward in the treatment of dyslipidemia, BMC Med., 13, 258, 10.1186/s12916-015-0503-4
Schwartz, 2014, Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial, Am Heart J., 168, 682, 10.1016/j.ahj.2014.07.028
Sabatine, 2016, Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial, Am Heart J., 173, 94, 10.1016/j.ahj.2015.11.015
Reiner, 2015, PCSK9 inhibitors--past, present and future, Expert Opin Drug Metab Toxicol., 11, 1517, 10.1517/17425255.2015.1075506
Nerbrand, 2002, Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides, Maturitas., 42, 55, 10.1016/S0378-5122(01)00302-4
Dupuy, 2008, Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents, Climacteric., 11, 74, 10.1080/13697130701877108
Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial, JAMA., 288, 321, 10.1001/jama.288.3.321
Grady, 2002, Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II), JAMA., 288, 49, 10.1001/jama.288.1.49
2012, North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society, Menopause., 19, 257, 10.1097/gme.0b013e31824b970a
Raitakari, 1994, Effects of persistent physical activity and inactivity on coronary risk factors in children and young adults. The Cardiovascular Risk in Young Finns Study, Am J Epidemiol., 140, 195, 10.1093/oxfordjournals.aje.a117239
Rifkind, 1999, When should patients with heterozygous familial hypercholesterolemia be treated?, JAMA., 281, 180, 10.1001/jama.281.2.180
Sorensen, 1994, Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level, J Clin Invest., 93, 50, 10.1172/JCI116983
Tonstad, 1996, Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects, Arterioscler Thromb Vasc Biol., 16, 984, 10.1161/01.ATV.16.8.984
Hegele, 1997, Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis, Clin Biochem., 30, 183, 10.1016/S0009-9120(96)00167-1
Assouline, 1995, Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population, Pediatrics., 96, 239, 10.1542/peds.96.2.239
Gotto, 2004, Targeting high-risk young patients for statin therapy, JAMA., 292, 377, 10.1001/jama.292.3.377
Sinzinger, 1992, Treatment of hypercholesterolaemia in children, Lancet., 340, 548, 10.1016/0140-6736(92)91745-T
Sinzinger, 1994, Sleep disturbance and appetite loss after lovastatin, Lancet., 343, 973, 10.1016/S0140-6736(94)90094-9
Knipscheer, 1996, Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia, Pediatr Res., 39, 867, 10.1203/00006450-199605000-00021
Lambert, 1996, Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group, Pediatrics., 97, 619, 10.1542/peds.97.5.619
Stein, 1999, Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial, JAMA., 281, 137, 10.1001/jama.281.2.137
Dirisamer, 2003, The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation, Eur J Pediatr., 162, 421, 10.1007/s00431-003-1181-3
McCrindle, 2003, Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multi-center, randomized, placebo-controlled trial, J Pediatr., 143, 74, 10.1016/S0022-3476(03)00186-0
Wiegman, 2004, Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial, JAMA., 292, 331, 10.1001/jama.292.3.331
Tonstad, 1996, Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia, J Pediatr., 129, 42, 10.1016/S0022-3476(96)70188-9
Tonstad, 1996, Low dose colestipol in adolescents with familial hypercholesterolaemia, Arch Dis Child., 74, 157, 10.1136/adc.74.2.157
Liacouras, 1993, Use of cholestyramine in the treatment of children with familial combined hyperlipidemia, J Pediatr., 122, 477, 10.1016/S0022-3476(05)83444-4
Salen, 2004, Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia, Circulation., 109, 966, 10.1161/01.CIR.0000116766.31036.03
Colletti, 1993, Niacin treatment of hypercholesterolemia in children, Pediatrics., 92, 78, 10.1542/peds.92.1.78
Blake, 2002, Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women, Circulation., 106, 1930, 10.1161/01.CIR.0000033222.75187.B9
Witte, 2004, Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis, J Lipid Res., 45, 1069, 10.1194/jlr.M300395-JLR200
Ensign, 2006, Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics, Clin Chem., 52, 1722, 10.1373/clinchem.2005.059949
Anderson, 2014, ACC/ AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol., 63, 2304, 10.1016/j.jacc.2014.03.016
Neumann, 2014, Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold, N Engl J Med., 371, 796, 10.1056/NEJMp1405158
Detsky, 1990, A clinician’s guide to cost-effectiveness analysis, Ann Intern Med., 113, 147, 10.7326/0003-4819-113-2-147
Martikainen, 2007, Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach, Eur J Cardiovasc Prev Rehabil., 14, 265, 10.1097/01.hjr.0000216550.74258.12
Delahanty, 2001, Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial, J Am Diet Assoc., 101, 1012, 10.1016/S0002-8223(01)00250-4
Sikand, 2000, Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance, J Am Diet Assoc., 100, 218, 10.1016/S0002-8223(00)00066-3
Elixhauser, 1990, The costs of smoking and the cost effectiveness of smoking-cessation programs, J Public Health Policy., 11, 218, 10.2307/3342753
Probstfield, 2003, How cost-effective are new preventive strategies for cardiovascular disease?, Am J Cardiol., 91, 22G, 10.1016/S0002-9149(03)00229-7
Franco, 2007, Primary prevention of cardiovascular disease: cost-effectiveness comparison, Int J Technol Assess Health Care., 23, 71, 10.1017/S0266462307051598
Howard, 2008, Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers, Pharmacoeconomics., 26, 497, 10.2165/00019053-200826060-00004
Hollis, 2007, The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline, Tob Control., 16, i53, 10.1136/tc.2006.019794
Plosker, 2007, Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events, Pharmacoeconomics., 25, 1031, 10.2165/00019053-200725120-00005
Ohsfeldt, 2008, Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications, Value Health., 11, 1061, 10.1111/j.1524-4733.2008.00354.x
Odden, 2015, Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States, Ann Intern Med., 162, 533, 10.7326/M14-1430
Kazi, 2016, Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, JAMA., 316, 743, 10.1001/jama.2016.11004
Gandra, 2016, Cost-Effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States, Clin Cardiol., 39, 313, 10.1002/clc.22535
Hay, 2005, Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease, Pharmacoeconomics., 23, 133, 10.2165/00019053-200523020-00005
Nyman, 2002, Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial, Arch Intern Med., 162, 177, 10.1001/archinte.162.2.177
Kohli, 2006, Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada, Pharmacoeconomics., 24, 815, 10.2165/00019053-200624080-00007
Ara, 2008, Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation, Health Technol Assess, 12, xi
Mihaylova, 2016, Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP), Am J Kidney Dis., 67, 576, 10.1053/j.ajkd.2015.09.020
Hilleman, 1999, A population-based treat-to-target pharmaco-economic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia, Clin Ther., 21, 536, 10.1016/S0149-2918(00)88308-3
Plans-Rubio, 2006, Cost-effectiveness analysis of cholesterol-lowering therapies in Spain, Am J Cardiovasc Drugs., 6, 177, 10.2165/00129784-200606030-00005